IICRT
International Institute of Clinical Research & Training
Home
White Papers
White Papers
Written by: Michael Rosenberg, M.D., MPH
Nobody likes hard times, but they do have one redeeming quality: They focus attention on areas neglected in good times. The need for greater efficiency is a prime example, especially for small drug development companies. Even in the best of times, they must cope with the formidable combination of high costs, long timelines, and low success rates. And when hard times come, they feel it first and most acutely. These companies should be the first to ask: Is there a better way?

Evolving Role Of Pharmacovigilance
Life Science Leader, October 2009
Written by: Dan Schell
New global regulations have forced the concept of pharmacovigilance to expand beyond just identifying adverse events.
Today pharmacovigilance is on the minds of every pharma and bio executive, and it starts earlier in the drug
development process
View More Articles
Life Science Leader, October 2009
Written by: Dan Schell
New global regulations have forced the concept of pharmacovigilance to expand beyond just identifying adverse events.
Today pharmacovigilance is on the minds of every pharma and bio executive, and it starts earlier in the drug
View More Articles